Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Highlights in breast cancer at ESMO 2024: KEYNOTE-522

Oleg Gluz • 15 Sep 2024
ESMO 2024
Breast Cancer
KEYNOTE-522

Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, explores key highlights in breast cancer presented at the European Society for Medical Oncology (ESMO) 2024 Congress, including overall survival data from the KEYNOTE-522 trial (NCT03036488) in patients with triple-negative breast cancer treated with immunotherapy. Additionally, Dr Gulz discusses the benefits of hypofractionated radiotherapy in patients with early breast cancer. This interview took place at the ESMO 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Oleg Gluz

Do chemotherapy-free approaches have a role in HER2+ early breast cancer?
1:44
Do chemotherapy-free approaches have a role in HER2+ early breast cancer?
Oleg Gluz • 15 Sep 2024
Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancer
1:25
Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancer
Oleg Gluz • 15 Sep 2024
WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancer
3:24
WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancer
Oleg Gluz • 15 Sep 2024
Breast cancer at ESMO 2023: ADCs and MONARCH 3
0:49
Breast cancer at ESMO 2023: ADCs and MONARCH 3
Oleg Gluz • 22 Oct 2023

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals